BROADCASTS.com

b'Credits: 0.25 AMA PRA Category 1 Credit\\u2122\\xa0CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-268\\nOverview: This episode will help bring awareness to the importance of educating patients about post-exposure prophylaxis (PrEP) in the primary care setting. This talk will also discuss how to reduce the stigma surrounding this prevention method. Finally, you will hear about the newly FDA approved PrEP treatment option that could potentially improve outcomes for patients.\\xa0\\xa0Episode resource links:\\n\\nhttps://www.healio.com/news/infectious-disease/20211220/fda-approves-first-longacting-injectable-for-hiv-preventionPhilbin, M. M., Parish, C., Kinnard, E. N., Reed, S. E., Kerrigan, D., Alcaide, M. L., ... & Metsch, L. R. (2021). Interest in long-acting injectable pre-exposure prophylaxis (LAI PrEP) among women in the women\\u2019s interagency HIV study (WIHS): a qualitative study across six cities in the United States. AIDS and Behavior, 25(3), 667-678.\\n\\xa0\\n\\n\\nKim Y. S. (2021). Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention. Infection & chemotherapy, 53(4), \\xa0 \\xa0 \\xa0686\\u2013695. https://doi.org/10.3947/ic.2021.0136\\n\\xa0\\n\\n\\nCDC Practice guidelines \\xa0https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf\\n\\nGuest: Mariyan L. Montaque, DNP, FNP-BC\\xa0Music Credit: Richard Onorato'